|Trade names||Eurespal, Pneumorel|
|AHFS/Drugs.com||International Drug Names|
|Elimination half-life||14–16 hours|
|Excretion||Urine (90%), feces (~10%)|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||260.337 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Fenspiride (INN, brand names Eurespal, Pneumorel and others) is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases. The pharmacotherapeutic classification is antitussives. In Russia it was approved for the treatment of acute and chronic inflammatory diseases of ENT organs (ear, nose, throat) and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as for maintenance treatment of asthma. Russia, Romania, France and other European countries withdrew fenspiride-based drugs from the market due to the risk of QT prolongation and torsades de pointes. Fenspiride is known to have activity as an alpha-1 blocker.
- Montes B, Catalan M, Roces A, Jeanniot JP, Honorato JM (1993). "Single dose pharmacokinetics of fenspiride hydrochloride: phase I clinical trial". European Journal of Clinical Pharmacology. 45 (2): 169–72. doi:10.1007/bf00315501. PMID 7901024. S2CID 20605939.
- Płusa T, Nawacka D (December 1998). "[Efficacy and tolerance of fenspiride in adult patients with acute respiratory tract infections]". Polski Merkuriusz Lekarski. 5 (30): 368–71. PMID 10101527.
- "Эреспал (Eurespal) Prescribing Information. VIDAL Drug Compendium" (in Russian). Retrieved 6 February 2014.
- "Fenspiride containing medicinal products". European Medicines Agency. 2019-02-15. Retrieved 2019-06-12.
- Jankowski R (September 2002). "[ENT inflammation and importance of fenspiride]". Presse Med (in French). 31 Spec No 1: HS7–10. PMID 12378970.